Federal Jury in Dallas Finds Bard's IVC Blood Clot Filter Defective and Dangerous

Rhea-AI Summary

On July 23, 2021, a federal jury in Dallas found C.R. Bard's IVC blood clot filter defective, adding to a total of over $7 million in awards against the company. This marks the fourth jury ruling against Bard regarding these filters, which are linked to serious medical complications. The Recovery IVC filter caused significant issues when it fractured post-implantation. Lawyers representing affected individuals expressed intentions to continue pursuing cases until Bard acknowledges its responsibility for the product's safety risks.

Positive

• Recent jury verdicts reinforce claims against Bard, potentially pressuring the company to address product safety.

Negative

• Four federal juries have found Bard liable for defective IVC filters, leading to over $7 million in damages.
• The filters are reported to cause serious medical complications, including fracturing and internal injuries.
• No evidence supports the effectiveness of these filters in preventing pulmonary emboli.
• Bard faces over 8,000 similar lawsuits, indicating ongoing legal troubles and potential liability.

DALLAS, July 23, 2021 /PRNewswire/ -- For the fourth time since May, jurors in federal court have found that C.R. Bard's IVC blood clot filter is defective and responsible for injuries and complications. The latest verdict for trial lawyers at Dallas-based Martin Baughman brings combined monetary awards to more than $7 million.

"Four juries have now sent a crystal-clear message to Bard about these defective products," said Ben Martin, Martin Baughman trial lawyer. "We will continue trying these cases until Bard takes responsibility." 

Martin Baughman represents several hundred individuals who have suffered injuries and complications caused by Bard's line of IVC filters, which include the Recovery, G2, G2X, Eclipse, Meridian and Denali. The filters are inserted into a major vein, the inferior vena cava (IVC), to prevent blood clots from moving to the heart and lungs.    

The spider-shaped devices are known to tilt, perforate vein walls, and fracture, causing metal pieces to dislodge and migrate into internal organs and other structures in the body. In addition, there is no evidence that they are effective at preventing pulmonary emboli. Although the filters are marketed as being removable, testimony in trial underscored that removal is difficult or impossible, especially after breakage.   

At one time, Bard, a subsidiary of Becton, Dickinson and Company (NYSE: BDX), faced more than 8,000 similar lawsuits that were consolidated in multidistrict litigation in Phoenix. Martin Baughman and the firm's clients rejected a proposed settlement that was inadequate. Instead, the firm is moving forward with an aggressive schedule of individual trials across the U.S.    

In the Dallas case, jurors found that Bard's Recovery IVC filter caused serious medical complications when it fractured after being implanted. The verdict includes $386,250 in damages.

"Once again, jurors have heard the facts and agreed that these filters are dangerous," said trial lawyer Laura Baughman. "After recklessly marketing these products and placing profit over safety, it's time for Bard to acknowledge how risky they are." 

"We are very happy the jury held Bard accountable for Bard's misdeeds," said Charla Aldous of Aldous\Walker, Dallas, Texas, who tried the case with Mr. Martin in Dallas.

The case is Debra Branch v. C.R. Bard Inc.et al., case No. 3:19-cv-02130. The trial team included Mr. Martin, Ms. Aldous, Joshua Michaels and Emily Acosta of Martin Baughman, and Caleb Miller of Aldous\Walker. 

Martin Baughman attorneys have helped thousands of victims of accidents and injuries caused by catastrophic vehicular and trucking accidents, oil field explosions, medical and hospital negligence, medical device and pharmaceutical design defects, and personal injuries caused by negligence and gross negligence.  

Media Contact: 
Robert Tharp 
214-420-6011 
Robert@androvett.com  

View original content:https://www.prnewswire.com/news-releases/federal-jury-in-dallas-finds-bards-ivc-blood-clot-filter-defective-and-dangerous-301340316.html

SOURCE Martin Baughman

FAQ

What was the outcome of the July 2021 jury verdict regarding Bard's IVC filters?

A federal jury found Bard's IVC blood clot filter defective, awarding over $7 million in damages.

How many jury verdicts have been made against Bard for its IVC filters?

This is the fourth jury verdict against Bard regarding the safety of its IVC filters.

What issues are associated with Bard's IVC filters?

The IVC filters are linked to serious complications, including fracturing and perforating vein walls.

What is the current status of lawsuits against Bard for IVC filters?

Bard is facing over 8,000 lawsuits related to its IVC filters, with ongoing trials planned.

What damages were awarded in the latest Bard IVC filter case?

The latest jury awarded $386,250 in damages related to a defective Bard IVC filter.